Takeaways from the UH CINEMA Program

Key Takeaways

UH CINEMA addresses the complex needs of patients with overlapping cardiovascular, renal, and metabolic conditions through integrated care models.
Implementation challenges include coordinating multidisciplinary teams and managing resource allocation effectively.
The program has demonstrated positive outcomes in patient management and health metrics, indicating its effectiveness.
Future opportunities involve expanding the program's reach and refining care strategies to enhance CRM patient outcomes.

A panel of cardiometabolic risk management experts analyzes key takeaways from the UH CINEMA Program.

EP: 1.The Impact of CRM Diseases in the US: Burden, Prevalence, and Obesity

EP: 2.Strategies for Prevention and Screening of CRM Conditions

EP: 3.The Link Between Obesity and CRM Conditions

EP: 4.Challenges in Managing Co-Morbid CRM Conditions

EP: 5.Contemporary Guidelines for CRM Conditions

EP: 6.Reasons for Low Adherence to Guidelines for CRM Conditions

EP: 7.Overcoming Barriers to Prescribing First-Line Medications for CRM Conditions

EP: 8.Educational Initiatives to Enhance Guideline Adherence in CRM

EP: 9.Addressing Gaps in CKD, T2D, and CVD Guidelines

EP: 10.Care Coordination for High-Risk CRM Patients

Now Viewing

EP: 11.Takeaways from the UH CINEMA Program

EP: 12.Exploring the Kidney-CHAMP Study

EP: 13.Insights from the COORDINATE-Diabetes Trial

EP: 14.Coordinating Initiatives to Enhance CRM Care

EP: 15.Implementing CRM Learnings and Utilization of Telehealth

Video content above is prompted by the following:

Let’s discuss some initiatives we have championed at our institutions. What are these initiatives and how are they impacting the care of CRM patients? Dr. Neeland: Tell us about the University Hospitals Heart & Vascular Institute’s Center for Integrated and Novel Approaches in Vascular-Metabolic Disease (UH CINEMA).
How is the UH CINEMA program advancing health care for patients with overlapping heart, diabetes, and kidney issues?
What challenges have you experienced implementing this program?
What specific results can you share from this program?
What are future opportunities to improve CRM care based on this program?

This activity is supported by Boehringer Ingelheim Pharmaceuticals Inc. and Eli Lilly and Company who provided financial support for this program.